The effect of aging on migration, proliferation, and collagen expression of tenocytes in response to ciprofloxacin.
Quinolone-induced tendinopathy or tendon rupture tends to be age-related. However, the synergistic effects of quinolone and aging on tenocytes remained to be explored. Tenocytes intrinsic to rat Achilles tendon from two age groups (young: 2 months; and near senescent (old): 24 months) were treated with ciprofloxacin. Tenocyte migration and proliferation were assessed by transwell filter migration assay and MTT (3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) assay, respectively. Messenger RNA and protein expressions of types I and III collagen were determined by reverse transcription-polymerase chain reaction (RT/PCR) and Western blot analysis, respectively. Transwell filter migration assay revealed that ciprofloxacin inhibited tenocytes migration, which became more significant in old tenocytes (p < 0.05). The results of MTT assay revealed that tenocytes proliferation decreased after ciprofloxacin treatment (p < 0.05), which also became more significant in old tenocytes. The results of RT-PCR and Western blot analysis revealed that mRNA and protein expressions of type I collagen remained unchanged in either young or old tenocytes with ciprofloxacin treatment, whereas the expressions of type III collagen were down-regulated by ciprofloxacin, which was more significant in old tenocytes. In conclusion, aging potentiated the ciprofloxacin-mediated inhibition of migration, proliferation, and expression of type III collagen of tenocytes.
Department of Physical Medicine and Rehabilitation, Chang Gung Memorial Hospital at Linkou, College of Medicine, Chang Gung University, Taiwan.
Hsiang-Ning
HN
Chang
Jong-Hwei S
JH
Pang
Carl P C
CP
Chen
Pei-Chih
PC
Ko
Miao-Sui
MS
Lin
Wen-Chung
WC
Tsai
Yun-Ming
YM
Yang
D000375:Aging / Q000378:metabolism; D000818:Animals; D000890:Anti-Infective Agents / Q000009:adverse effects*; D002465:Cell Movement / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D002939:Ciprofloxacin / Q000009:adverse effects*; D024042:Collagen Type I / Q000378:metabolism; D024061:Collagen Type III / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D052256:Tendinopathy / Q000139:chemically induced* / Q000378:metabolism; D013710:Tendons / Q000166:cytology* / Q000378:metabolism
D000890:Anti-Infective Agents; D024042:Collagen Type I; D024061:Collagen Type III; D002939:Ciprofloxacin